Get Your Free Case Evaluation

Dupixent Lawsuit Help Center

Nationwide Injury Lawyers Investigating Dupixent (Dupilumab) Lawsuits for Cutaneous T-Cell Lymphoma (CTCL) and Related Cancers

Have You or a Loved One Been Diagnosed with T-Cell Lymphoma After Using Dupixent?



Dupixent (dupilumab), manufactured by Sanofi and Regeneron Pharmaceuticals, is a biologic injection widely prescribed for moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, and other inflammatory conditions. While it has helped many patients manage symptoms, emerging evidence and lawsuits suggest a serious risk: an increased chance of developing cutaneous T-cell lymphoma (CTCL), including subtypes like mycosis fungoides and Sézary syndrome.


Recent studies indicate Dupixent users may face a significantly higher risk of CTCL — sometimes 3–4 times greater than non-users. Lawsuits allege that the manufacturers failed to adequately warn patients and doctors about this potential cancer risk, including how the drug may mask early symptoms of lymphoma (often misdiagnosed as worsening eczema), delaying proper diagnosis and treatment.


If you used Dupixent and later received a CTCL or T-cell lymphoma diagnosis, you may be entitled to compensation for medical costs, lost income, pain and suffering, and more. Our nationwide network of experienced injury lawyers is here to help — contact us today for a free case review.

The Link Between Dupixent and Cutaneous T-Cell Lymphoma (CTCL)



Dupixent works by blocking certain proteins (IL-4 and IL-13) to reduce inflammation. However, this immune-modulating effect has raised concerns about cancer risks, particularly in patients with skin conditions like eczema that can mimic or overlap with early lymphoma symptoms.


Peer-reviewed studies (including 2024–2025 research in major dermatology and allergy journals) have shown Dupixent users with atopic dermatitis may have a substantially elevated risk of CTCL.

The FDA has investigated reports of CTCL linked to Dupixent, including a safety signal identified in late 2024–early 2025 after hundreds of adverse event reports.


Lawsuits claim manufacturers knew or should have known about these risks but failed to include adequate warnings on the label, leading to delayed diagnoses and worsened outcomes in some patients.


Wrongful death cases have already been filed where patients passed away from T-cell lymphoma shortly after starting Dupixent.


As of early 2026, lawsuits are in the early stages, with individual filings across federal courts and a motion pending to consolidate cases into multidistrict litigation (MDL) for efficiency.

What Is Cutaneous T-Cell Lymphoma (CTCL)?

Cutaneous T-cell lymphoma is a cancer of the immune system in which malignant T cells accumulate in the skin.

In its early stages, CTCL can closely resemble common skin conditions such as:


  • Eczema
  • Psoriasis
  • Chronic dermatitis
  • Unexplained rashes or plaques


Because these symptoms look similar to ordinary inflammatory skin disorders, CTCL can go undiagnosed for years. Many patients initially receive treatment for eczema before doctors eventually discover the underlying lymphoma.


Two of the most common forms of CTCL include:



  • Mycosis Fungoides
  • Sézary Syndrome



Both conditions can require long-term treatment and ongoing monitoring. In advanced cases, they may become life-threatening.

Why Dupixent Is Being Investigated

Dupixent lawsuits do not claim the drug causes cancer in every patient. Instead, many allege that Dupixent may:


  • Trigger CTCL in certain patients
  • Accelerate the progression of existing lymphoma
  • Mask symptoms and delay proper diagnosis
  • Suppress inflammation while underlying cancer progresses


Many reported cases follow a similar pattern:


  1. A patient is diagnosed with eczema or dermatitis.
  2. Dupixent is prescribed to treat the condition.
  3. Symptoms initially appear to improve.
  4. Then possibly, over time, the condition worsens or behaves differently than typical eczema.
  5. Further testing then may reveal cutaneous T-cell lymphoma. (CTCL)



Plaintiffs argue that clearer warnings could have led doctors to test for lymphoma earlier and potentially prevented delayed diagnosis and disease progression.

Dupixent Lawsuit Information

Dupixent may be responsible for CTCL cases, and those impacted may be due compensation.

Allegations in Dupixent Lawsuits

Recent lawsuits filed against drug manufacturers Regeneron Pharmaceuticals and Sanofi raise several allegations, including:


  • Dupixent may cause, worsen, or accelerate CTCL
  • The manufacturers may have known or should have known about the risk
  • The drug’s warning labels may not adequately disclose this risk
  • Doctors were possibly not advised to rule out CTCL before prescribing Dupixent
  • Continued treatment may delay diagnosis and worsen outcomes



Many lawsuits focus on failure-to-warn claims, as well as allegations of negligence and product liability.

Who May Qualify for a Dupixent Lawsuit?

You may qualify for a Dupixent lawsuit if:


  • You were prescribed Dupixent for eczema, asthma, or another approved condition
  • You were later diagnosed with cutaneous T-cell lymphoma
  • Your symptoms worsened or progressed while taking Dupixent
  • You were diagnosed with mycosis fungoides or Sézary syndrome
  • Your skin condition did not respond as expected to treatment


Every case is unique. Eligibility depends on medical history and diagnosis timelines.




📞 Call 888-385-8804 to see if you may qualify for a Dupixent lawsuit.

Possible Compensation in Dupixent Lawsuits

Compensation in Dupixent lawsuits may depend on factors such as:


  • The severity of the lymphoma diagnosis
  • Medical treatment required
  • Impact on work and daily life
  • Long-term health complications
  • Whether diagnosis was delayed


Potential compensation may include:


  • Medical expenses
  • Lost income
  • Pain and suffering
  • Long-term care costs


Every case is different.


Results cannot be guaranteed.

What Should You Do If You Took Dupixent?

If you or a loved one developed cutaneous T-cell lymphoma after taking Dupixent, it is important to have your medical history reviewed by attorneys familiar with pharmaceutical litigation.


An experienced lawyer can help:


  • Review your medical records
  • Determine whether you may qualify for a claim
  • Preserve evidence needed to support your case
  • Protect your rights under the statute of limitations


You may be able to pursue compensation without paying upfront legal fees.


Book your free, virtual case review now.

Why Choose Our Nationwide Dupixent Lawsuit Team?

Experienced in Pharmaceutical Lawsuit Litigation

We have a proven track record in handling pharmaceutical injury cases, including those involving antipsychotics and breast cancer risks.

Nationwide Service

Our lawyers represent clients across all 50 states, ensuring you get expert legal help no matter where you live.

No Up Front Fees

We work on a contingency basis – you pay nothing unless we win your case.

Compassionate Support

We understand the physical, emotional, and financial toll of breast cancer. Our team is here to support you every step of the way.

What Compensation May Be Available in a Dupixent Lawsuit?


Successful claims may recover damages for:


  • Medical expenses (past and future treatment, including cancer care)
  • Lost wages and diminished earning capacity
  • Pain, suffering, and emotional distress
  • Wrongful death benefits for families who lost a loved one

Get the Legal Support You Need Now

Schedule Your Free Consultation Today

Our team is ready to review your Risperdal case and provide clear guidance on your legal options. Contact us to discuss your situation and take the first step toward securing the compensation you deserve.

Contact Us